PMV Pharmaceuticals (PMVP) to Release Quarterly Earnings on Monday

PMV Pharmaceuticals (NASDAQ:PMVP) is expected to be announcing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 9:30 AM ET.

PMV Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ PMVP opened at $1.04 on Monday. The firm has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $1.30. PMV Pharmaceuticals has a 12 month low of $0.81 and a 12 month high of $1.84. The firm has a market capitalization of $55.34 million, a PE ratio of -0.65 and a beta of 1.40.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of PMV Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, PMV Pharmaceuticals has an average rating of “Hold” and a consensus price target of $5.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PMVP. Shay Capital LLC purchased a new position in shares of PMV Pharmaceuticals in the second quarter worth approximately $26,000. Squarepoint Ops LLC increased its holdings in PMV Pharmaceuticals by 101.8% during the fourth quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock valued at $33,000 after buying an additional 13,367 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in PMV Pharmaceuticals by 349.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock worth $34,000 after acquiring an additional 21,334 shares during the period. Algert Global LLC purchased a new position in shares of PMV Pharmaceuticals during the 3rd quarter worth $87,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of PMV Pharmaceuticals during the 3rd quarter worth $96,000. 90.20% of the stock is owned by hedge funds and other institutional investors.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.